Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
21
10
2020
received:
12
05
2020
accepted:
23
10
2020
pubmed:
28
10
2020
medline:
12
5
2021
entrez:
27
10
2020
Statut:
ppublish
Résumé
Hypertension and sarcopenia are commonly seen in older adults. The renin-angiotensin system and the therapeutic use of angiotensin-converting enzyme (ACE) inhibitors have been on the agenda of sarcopenia in different perspectives. Our aim was to explore the frequency of sarcopenia in patients with hypertension and to investigate the association between the use of ACE inhibitors and sarcopenia. A total of 272 community-dwelling adults were recruited. Anterior thigh muscle thickness was measured by ultrasound. Handgrip strength, gait speed, and chair stand test were evaluated. Low muscle mass was diagnosed in the presence of low sonographic thigh adjustment ratio (STAR) values and sarcopenia was diagnosed if low STAR values were coupled with low functional tests. 136 subjects (50.0%) had no comorbid disease; 102 (37.5%) had one, 21 (7.7%) had two, nine (3.3%) had three and four (1.5%) had four comorbid diseases. Both low muscle mass (41.9% vs 13.2%) and sarcopenia (32.2% vs 7.8%) were more commonly seen in hypertensive when compared with normotensive older adults. Subgroup analysis of older adults with hypertension revealed that sarcopenia was less prevalent (P = .003) in patients using ACE inhibitors (8.7%) than those using angiotensin II receptor blockers (48.7%) and other antihypertensive drugs (46.4%). After binary logistic regression analyses; only the presence of hypertension seemed to independently predict the development of sarcopenia in older adults [OR = 6.5 (95% CI: 2.4-17.8, P < .001)]. Sarcopenia is highly prevalent in hypertensive older adults. Amongst many antihypertensive medications, ACE inhibitors seem to have favourable effects on both disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertension and sarcopenia are commonly seen in older adults. The renin-angiotensin system and the therapeutic use of angiotensin-converting enzyme (ACE) inhibitors have been on the agenda of sarcopenia in different perspectives. Our aim was to explore the frequency of sarcopenia in patients with hypertension and to investigate the association between the use of ACE inhibitors and sarcopenia.
METHODS
METHODS
A total of 272 community-dwelling adults were recruited. Anterior thigh muscle thickness was measured by ultrasound. Handgrip strength, gait speed, and chair stand test were evaluated. Low muscle mass was diagnosed in the presence of low sonographic thigh adjustment ratio (STAR) values and sarcopenia was diagnosed if low STAR values were coupled with low functional tests.
RESULTS
RESULTS
136 subjects (50.0%) had no comorbid disease; 102 (37.5%) had one, 21 (7.7%) had two, nine (3.3%) had three and four (1.5%) had four comorbid diseases. Both low muscle mass (41.9% vs 13.2%) and sarcopenia (32.2% vs 7.8%) were more commonly seen in hypertensive when compared with normotensive older adults. Subgroup analysis of older adults with hypertension revealed that sarcopenia was less prevalent (P = .003) in patients using ACE inhibitors (8.7%) than those using angiotensin II receptor blockers (48.7%) and other antihypertensive drugs (46.4%). After binary logistic regression analyses; only the presence of hypertension seemed to independently predict the development of sarcopenia in older adults [OR = 6.5 (95% CI: 2.4-17.8, P < .001)].
CONCLUSIONS
CONCLUSIONS
Sarcopenia is highly prevalent in hypertensive older adults. Amongst many antihypertensive medications, ACE inhibitors seem to have favourable effects on both disorders.
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13800Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104.
Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-968.
Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21.
Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med Res Rev. 2015;35:437-463.
Kara M, Kaymak B, Ata AM, et al. STAR-sonographic thigh adjustment ratio: a golden formula for the diagnosis of sarcopenia. Am J Phys Med Rehabil. 2020;99:902-908.
Pinheiro PA, Carneiro JA, Coqueiro RS, Pereira R, Fernandes MH. "Chair Stand Test" as simple tool for sarcopenia screening in elderly women. J Nutr Health Aging. 2016;20:56-59.
Özçakar L, Kara M, Quittan M, Ata AM, Michail X, Kaymak B. The need for an integrative musculoskeletal approach in sarcopenia: the ISarcoPRM Kickstart. Eur J Phys Rehabil Med. 2020;56:535-536.
Dodds RM, Syddall HE, Cooper R, et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014;9:e113637.
Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(300-7):e2.
Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106.
Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: a systematic review and meta-analysis. Exp Gerontol. 2020;131:110801.
Castillo-Olea C, Garcia-Zapirain Soto B, Zuñiga C. Evaluation of prevalence of the sarcopenia level using machine learning techniques: Case study in Tijuana Baja California, Mexico. Int J Environ Res Public Health. 2020;17:1917.
Han K, Park YM, Kwon HS, et al. Sarcopenia as a determinant of blood pressure in older Koreans: findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008-2010. PLoS One. 2014;9:e86902.
Park SH, Park JH, Song PS, et al. Sarcopenic obesity as an independent risk factor of hypertension. J Am Soc Hypertens. 2013;7:420-425.
Ata AM, Kara M, Kaymak B, Özçakar L. Sarcopenia Is Not "Love": You Have to Look Where You Lost it!. Am J Phys Med Rehabil. 2020;99:e119-e120.
Abe T, Sakamaki M, Yasuda T, et al. Age-related, site-specific muscle loss in 1507 Japanese men and women aged 20 to 95 years. J Sports Sci Med. 2011;10:145-150.
Burton LA, McMurdo ME, Struthers AD. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? Clin Endocrinol (Oxf). 2011;75:725-729.
Fonseca Alves DJ, Bartholomeu-Neto J, Júnior ER, Ribeiro Zarricueta BS, Nóbrega OT, Córdova C. Walking speed, risk factors, and cardiovascular events in older adults-systematic review. J Strength Cond Res. 2017;31:3235-3244.
Dumurgier J, Elbaz A, Dufouil C, Tavernier B, Tzourio C. Hypertension and lower walking speed in the elderly: the Three-City study. J Hypertens. 2010;28:1506-1514.
Zhang X, Huang L, Peng X, et al. Association of handgrip strength with hypertension among middle-aged and elderly people in Southern China: A cross-sectional study. Clin Exp Hypertens. 2020;42:190-196.
Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al. American college of sports medicine position stand. Exercise and physical activity for older adults. Med Sci Sports Exerc. 2009;41:1510-1530.
Miszko TA, Cress ME, Slade JM, Covey CJ, Agrawal SK, Doerr CE. Effect of strength and power training on physical function in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2003;58:171-175.
Onder G, Penninx BWJH, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359:926-930.
Buford TW, Manini TM, Hsu F-C, et al. Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise. J Am Geriatr Soc. 2012;60:1244-1252.
Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014;69:736-743.
Baptista LC, Machado-Rodrigues AM, Veríssimo MT, et al. Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medication. Exp Gerontol. 2018;109:82-89.
Coelho-Júnior HJ, Gambassi BB, Irigoyen M-C, et al. Hypertension, sarcopenia, and global cognitive function in community-dwelling Older Women: a preliminary study. J Aging Res. 2018;2018:9758040.
Takeshita H, Yamamoto K, Mogi M, Nozato S, Horiuchi M, Rakugi H. Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice. Hypertens Res. 2020;43:296-304.
Di Bari M, Van De Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: The Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52:961-966.
Wicklmayr M, Dietze G, Brunnbauer H, Rett K, Mehnert H. Dose-dependent effect of bradykinin on muscular blood flow and glucose uptake in man. Hoppe Seylers Z Physiol Chem. 1983;364:831-833.
Popadic Gacesa JZ, Momcilovic M, Veselinovic I, Brodie DA, Grujic NG. Bradykinin type 2 receptor -9/-9 genotype is associated with triceps brachii muscle hypertrophy following strength training in young healthy men. BMC Musculoskelet Disord. 2012;13:217.